Follow the people · Insider
Daniel Tardiff
Daniel Tardiff files insider transactions with the SEC as a chief scientific officer of Camp4 Therapeutics (CAMP). We hold 1 disclosed purchase or sale filed since 22 December 2025, 1 of them in the last 90 days.
- Files forCAMP
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure19 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 11 December 2025 — 19 August 2026Chief Scientific Officer · Camp4 Therapeutics (CAMP)3 Form 4 lines · source: SEC Form 4
Everything they disclosed
3 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 1,738 shares of Camp4 TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- was granted 170,000 shares of Camp4 Therapeutics (a derivative holding)SEC Form 43 April 2026Stock Option (Right to Buy) · traded 1 April 2026 · filed 3 April 2026
- was granted 145,500 shares of Camp4 Therapeutics (a derivative holding)SEC Form 422 December 2025Stock Option (Right to Buy) · traded 11 December 2025 · filed 22 December 2025
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.